Birmingham Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.85M Hold
23,240
2.22% 12
2026
Q1
$5.05M Sell
23,240
-875
-4% -$194K 2.13% 13
2025
Q4
$5.51M Sell
24,115
-75
-0.3% -$17.1K 2.43% 12
2025
Q3
$5.6M Sell
24,190
-1,600
-6% -$326K 2.57% 11
2025
Q2
$4.79M Sell
25,790
-4,757
-16% -$884K 2.12% 14
2025
Q1
$6.4M Hold
30,547
2.41% 12
2024
Q4
$5.43M Sell
30,547
-75
-0.2% -$13.8K 2.01% 16
2024
Q3
$6.05M Buy
30,622
+900
+3% +$168K 2.2% 16
2024
Q2
$5.1M Hold
29,722
1.99% 18
2024
Q1
$5.41M Sell
29,722
-600
-2% -$103K 1.99% 18
2023
Q4
$4.7M Sell
30,322
-80
-0.3% -$11.7K 1.86% 18
2023
Q3
$4.53M Buy
30,402
+725
+2% +$106K 1.87% 18
2023
Q2
$4M Sell
29,677
-1,323
-4% -$194K 1.67% 20
2023
Q1
$4.94M Buy
31,000
+20
+0.1% +$3.06K 1.97% 18
2022
Q4
$5.01M Hold
30,980
1.9% 19
2022
Q3
$4.16M Buy
30,980
+500
+2% +$71.7K 1.84% 20
2022
Q2
$4.67M Hold
30,480
1.86% 21
2022
Q1
$4.94M Sell
30,480
-750
-2% -$109K 1.72% 19
2021
Q4
$4.23M Hold
31,230
1.53% 24
2021
Q3
$3.37M Sell
31,230
-800
-2% -$91.4K 1.29% 28
2021
Q2
$3.61M Hold
32,030
1.32% 27
2021
Q1
$3.47M Sell
32,030
-200
-0.6% -$21.4K 1.3% 28
2020
Q4
$3.45M Buy
32,230
+1,040
+3% +$99.9K 1.43% 26
2020
Q3
$2.73M Buy
31,190
+1,360
+5% +$128K 1.24% 30
2020
Q2
$2.93M Buy
29,830
+550
+2% +$48.4K 1.43% 25
2020
Q1
$2.23M Sell
29,280
-1,000
-3% -$85.2K 1.23% 27
2019
Q4
$2.68M Sell
30,280
-850
-3% -$70.6K 1.19% 28
2019
Q3
$2.36M Buy
31,130
+1,900
+7% +$130K 1.09% 34
2019
Q2
$2.13M Buy
29,230
+60
+0.2% +$4.72K 0.96% 36
2019
Q1
$2.35M Buy
29,170
+1,350
+5% +$110K 1.05% 35
2018
Q4
$2.56M Buy
27,820
+172
+0.6% +$15.1K 1.25% 30
2018
Q3
$2.62M Hold
27,648
1.08% 35
2018
Q2
$2.56M Hold
27,648
1.1% 36
2018
Q1
$2.62M Sell
27,648
-300
-1% -$33K 1.09% 35
2017
Q4
$2.7M Sell
27,948
-100
-0.4% -$9.43K 1.03% 34
2017
Q3
$2.49M Hold
28,048
0.99% 35
2017
Q2
$2.03M Sell
28,048
-800
-3% -$53.8K 0.82% 44
2017
Q1
$1.88M Buy
28,848
+380
+1% +$23.9K 0.76% 44
2016
Q4
$1.78M Hold
28,468
0.75% 44
2016
Q3
$1.76M Sell
28,468
-135
-0.5% -$8.74K 0.78% 41
2016
Q2
$1.77M Hold
28,603
0.78% 41
2016
Q1
$1.63M Sell
28,603
-100
-0.3% -$5.57K 0.66% 46
2015
Q4
$1.7M Hold
28,703
0.69% 47
2015
Q3
$1.56M Sell
28,703
-750
-3% -$48.8K 0.68% 49
2015
Q2
$1.98M Sell
29,453
-150
-0.5% -$9.79K 0.77% 45
2015
Q1
$1.73M Buy
29,603
+140
+0.5% +$8.46K 0.66% 52
2014
Q4
$1.93M Hold
29,463
0.74% 45
2014
Q3
$1.7M Sell
29,463
-600
-2% -$33.3K 0.65% 52
2014
Q2
$1.7M Sell
30,063
-430
-1% -$22.6K 0.62% 49
2014
Q1
$1.57M Sell
30,493
-112
-0.4% -$5.66K 0.59% 52
2013
Q4
$1.62M Sell
30,605
-675
-2% -$33.2K 0.61% 53
2013
Q3
$1.4M Sell
31,280
-3,800
-11% -$168K 0.55% 56
2013
Q2
$1.45M Buy
+35,080
New +$1.53M 0.6% 55

Other funds holding ABBV

Birmingham Capital Management's ABBV Position: Q2 2026 in Review

Birmingham Capital Management held its AbbVie (ABBV) position steady in Q2 2026 at 23,240 shares worth $5.85M. The position accounts for 2.22% of the portfolio, ranked #12.

Birmingham Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.4M in Q1 2025. 4,191 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Birmingham Capital Management held 23,240 shares of AbbVie worth $5.85M as of Q2 2026.
  • Birmingham Capital Management left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 2.22% of Birmingham Capital Management's portfolio in Q2 2026, its #12 holding.
  • Birmingham Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Birmingham Capital Management's AbbVie position peaked at $6.4M in Q1 2025.
  • 4,191 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Birmingham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.